Predilife - Asset Resilience Ratio
Predilife (ALPRE) has an Asset Resilience Ratio of 16.23% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ALPRE total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Predilife's Asset Resilience Ratio has changed over time. See ALPRE net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Predilife's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALPRE market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €212.11K | 16.23% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €212.11K | 16.23% |
Asset Resilience Insights
- Good Liquidity Position: Predilife maintains a healthy 16.23% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Predilife Industry Peers by Asset Resilience Ratio
Compare Predilife's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 57.28% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Predilife (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Predilife.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.69% | €701.00K ≈ $819.54K |
€2.44 Million ≈ $2.86 Million |
+7.86pp |
| 2023-12-31 | 20.82% | €1.84 Million ≈ $2.15 Million |
€8.82 Million ≈ $10.31 Million |
+16.85pp |
| 2022-12-31 | 3.98% | €188.86K ≈ $220.80K |
€4.75 Million ≈ $5.55 Million |
-0.81pp |
| 2021-12-31 | 4.79% | €189.80K ≈ $221.89K |
€3.97 Million ≈ $4.64 Million |
+0.58pp |
| 2020-12-31 | 4.21% | €172.54K ≈ $201.71K |
€4.10 Million ≈ $4.79 Million |
-8.51pp |
| 2019-12-31 | 12.72% | €171.72K ≈ $200.76K |
€1.35 Million ≈ $1.58 Million |
+8.73pp |
| 2018-12-31 | 3.99% | €92.00K ≈ $107.56K |
€2.31 Million ≈ $2.70 Million |
-18.29pp |
| 2016-12-31 | 22.28% | €551.66K ≈ $644.95K |
€2.48 Million ≈ $2.89 Million |
-- |
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer pred… Read more